Press Release
New Publication Supports the Role of SeptiCyte® RAPID To Improve Infection Diagnosis in Post Surgery and Trauma Patients
The study demonstrates strong performance distinguishing infection from sterile inflammation in post-op and trauma patients, when routine tests aren’t reliable. SEATTLE, WA, UNITED STATES, September 2, 2026 /EINPresswire.com/ — Immunexpress, a molecular diagnostics company focused on improving outcomes for patients with suspected sepsis, today announced the publication of a new study which highlights the potential of SeptiCyte® RAPID to address…
Read MoreImmunexpress Presenting at the Society of Critical Care Medicine (SCCM) 2026 Critical Care Congress Showing SeptiCyte RAPID® High Correlation with Blood Culture Positive Sepsis Patients
SEATTLE and BRISBANE, Australia, March 23, 2026 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced its participation, including the presentation of a poster, at the Society of Critical Care Medicine (SCCM) 2026 Critical Care Congress in Chicago, Illinois, from March 22-24th 2026. Immunexpress Chief Medical Officer Dr.…
Read MoreImmunexpress Announces Publication Demonstrating SeptiCyte RAPID® Utility for Differentiating Infection from Sterile Inflammation in Readmitted Bone Marrow Transplant Patients with Febrile Neutropaenia
Study supports utility of host-response testing in febrile neutropenia patients with haematological malignancies which may be the only indication of severe underlying infections SEATTLE and BRISBANE, Australia, Feb. 25, 2026 /PRNewswire/ — Immunexpress, a molecular diagnostics company focused on improving outcomes for patients with suspected sepsis, today announced the publication of a new study demonstrating…
Read MoreImmunexpress Announces Publication Showing SeptiCyte RAPID® Identifies Septic Patients Most Likely to Have Positive Blood Cultures
Publication highlights strong association between a patient’s sepsis risk and likelihood of positive cultures, with SeptiCyte RAPID results just 90 minutes after a blood draw SEATTLE and BRISBANE, Australia, Feb. 12, 2026 /PRNewswire/ — Immunexpress, a molecular diagnostics company focused on improving outcomes for patients with suspected sepsis, today announced the publication of a new multi-center…
Read MoreImmunexpress’ Sepsis Test Receives Regulatory Clearance from Australian Therapeutic Goods Administration (TGA) for Paediatric Patients Suspected of Sepsis
SeptiCyte RAPID® is the 1st and only test included in the ARTG for paediatric sepsis testing, which makes it a game changer in the battle against a life-threatening condition SEATTLE and BRISBANE, Australia, January 20 2026 – Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced that…
Read More2 New Published Studies Highlight SeptiCyte RAPID’s Strong Performance and Clinical Utility in Post Cardiac Surgery Patients
SeptiCyte® RAPID scales with other measures of infection and clinical severity and outperforms traditional biomarkers in discriminating infection status SEATTLE and BRISBANE, Australia, Oct. 23, 2025 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced publication of two studies in the International Journal of Molecular Sciences and Journal of Critical…
Read MoreStudy Published in the Journal Infection Demonstrates Clinical Utility of SeptiCyte® RAPID to Diagnose Sepsis in Critically Ill Patients with Hospital Acquired Infections
From the PR Newswire post SeptiCyte® RAPID outperformed traditional inflammatory biomarkers of procalcitonin and C-reactive protein SEATTLE and BRISBANE, Australia, Sept. 17, 2025 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced the publication of a study in the journal Infection. The article, entitled, “Blood transcriptomic for the diagnosis of nosocomial…
Read MoreNew Online Poll Reveals Support for Host Response Testing in Antibiotic Stewardship Among Healthcare Professionals and Patient Advocates
73% of respondents agree that host response testing helps guide antibiotic stewardship efforts SEATTLE and BRISBANE, Australia, June 10, 2025 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced the results from an online poll conducted during the Sepsis Alliance AMR Conference on April 30, 2025.…
Read MoreImmunexpress to Present New Data at the Society of Critical Care Medicine (SCCM) 2025 Critical Care Congress
SEATTLE and BRISBANE, Australia, Feb. 24, 2025 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced its participation, including the presentation of two posters, at the Society of Critical Care Medicine (SCCM) 2025 Critical Care Congress in Orlando, Florida, from February 23 – 25, 2025.…
Read MoreJournal of Clinical Medicine Publication Demonstrates Clinical Utility of SeptiCyte® RAPID in Critically Ill Heterogeneous Patient Populations
SeptiCyte® RAPID demonstrated consistent performance in discriminating sepsis from Systemic Inflammatory Response Syndrome (SIRS) regardless of demographics or the presence or absence of medical conditions SEATTLE and BRISBANE, Australia, Oct. 16, 2024 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostics company focused on improving outcomes for suspected sepsis patients, today announced the publication of a study in the Journal of…
Read More